Shares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than ...

After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going ...

Quick Read Large-cap biotech stocks face patent cliffs and biosimilar competition rather than AI-driven disruption, but ...

Today, Incubate and the National Security Commission on Emerging Biotechnology (NSCEB) convened venture capital investors, NSCEB commissioners and staff, and congressional offices on Capitol Hill for ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Boundless Bio's first direct ecDNA-targeting asset, is entering clinical trials with promising preclinical efficacy. Check ...

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in ...

Biotechnology drives cutting-edge medical innovation but is constrained by Europe’s fragmented regulatory landscape. The ...